News | October 24, 2013

First Patients Treated With Cardioband Annuloplasty System for Transcatheter Mitral Repair Show Promising Results

heart valve repair clinical trial study valtech cardio cardioband annuloplasty
October 24, 2013 — Valtech Cardio Ltd., a medical device company that develops solutions for mitral valve repair and replacement, said 11 patients have been treated with the company's transcatheter (transfemoral) Cardioband Annuloplasty System in three European medical centers.
 
A clinical update on the Cardioband study will be presented at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium in San Francisco on Oct. 30-31.
 
The Cardioband device enables transcatheter mitral regurgitation (MR) repair, thereby avoiding open-heart surgery and the use of cardiac bypass machine. Another advantage is that the size of the Cardioband is fitted while the heart is beating, which optimizes the results of the repair. The form and clinical function of the Cardioband closely replicates that of the annuloplasty rings that are the standard-of-care in surgery.
 
The patients were treated as part of an ongoing multi-center study at the Asklepios Klinik St. Georg Heart Center in Hamburg, Bichat-Claude Bernard Hospital in Paris and San Raffaele Hospital in Milan. The objective was to study the safety of Valtech's Transfemoral Cardioband Annuloplasty System in patients suffering from functional MR who were at high risk for open-heart surgery. The study focused on the overall rate of Major Cardiovascular adverse events (MACE) until hospital discharge and at post-operative 30 days.
 
"The safety profile of the device is impressive,” said Francesco Maisano, chief medical officer, Valtech. “Throughout these 11 procedures, the Cardioband device has demonstrated an excellent safety profile with no MACE to date…. Cardioband is the most promising valve repair technology. Early outcomes are extremely favorable with profound reduction of MR in most patients."
 
All patients that have been implanted with the Cardioband system have experienced a reduction in the mitral valve annular size and an increase in coaptation length. To date, two patients have completed six months follow-up demonstrating a stable improvement from severe MR to mild MR while nine patients were discharged with mild or no MR.
 
"We have been waiting for a long time for a transcatheter treatment for mitral regurgitation that can reproduce an effective surgical technique,” said Alec Vahanian, principal investigator, Bichat-Claude Bernard Hospital, Paris, who implanted five patients. “The preliminary results we now have with Cardioband suggest that the Cardioband can do it."
 
"The Cardioband annuloplasty system provides an excellent alternative for patients who are at high risk to undergo surgery,” said Karl-Heinz Kuck, principal investigator, Asklepios Klinik, St. Georg Heart Center, Hamburg. “The procedure is safe and has the potential to become the first-line interventional therapy."
 
Valtech Cardio plans to expand the study in the next few months by recruiting additional heart centers throughout Europe. Data from the trial will be used to support and obtain the CE mark and other international regulatory approvals. The company expects to complete enrollment in the first half of 2014.
 
For more information: www.valtechcardio.com
 

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init